

WYDUR Board Meeting Minutes
Thursday, November 29, 2007
Casper, Wyoming
11 a.m. – 3 p.m.

Members present: Steve Brown, Mike Carpenter, Bill Harrison, Kurt Hopfensperger, Richard Johnson, Scott Johnston, Bill Keenan, Tonja Woods

Excused: Becky Drnas, Kevin Robinett, Dean Winsch

Ex-officio: Roxanne Homar, Antoinette Brown, Donna Artery, James Bush, Melissa Hunter

Guests: Steen Goddik (incoming member), Barbara Lussenhop (Roche), Michael Dunn (Pfizer), Elizabeth Gunther (Janssen/Johnson and Johnson), Courtney Smith (Janssen/Johnson and Johnson), Tim Hynek (Eli Lilly), John Stockton (Genentech)

Dr. Harrison called the meeting to order at 11:04 a.m.

Introductions were made. Aimee announced the appointment of new members, Tonja Woods and Dr. Steen Goddik. The Board is taking nominations for PA's/NP's to replace Mike Carpenter.

Minutes of September 2007

The minutes of the September 27, 2007 meeting were approved as presented.

Department of Health

The Governor's budget will be released Friday November 30th. Pharmacy is doing well.

On November 21st, a request for proposals was released for MMIS Services and Takeover. This includes MMIS, PBM and dental services.

Epocrates is now available for Blackberry at no charge. Medicaid currently has 203 users accessing its preferred drug list.

Old Business

Public comments were reviewed for the antidepressant criteria. The Board recommended that it be made clear that these criteria were based on psychiatry best practices as well as cost. The following criteria were approved.

Final step utilization for antidepressants
WY-DUR Board
11/29/07

Step 1 for all clients:
One trial required

citalopram (all strengths)
Fluoxetine (all strengths)
Bupropion (immediate release only)

Step 2 for all clients:
Two trials required

sertraline (all strengths)
paroxetine (all strengths)
Bupropion (SR formulations and Wellbutrin XL)
Mirtazapine (all generic strengths)
Venlafaxine (immediate release)

Step 3 for all clients:

Cymbalta (all strengths)
*PA will **NOT** be required for a diagnosis of diabetic
peripheral neuropathy
Lexapro (all strengths)
Effexor XR

Medications not
Requiring PA:

trazodone and nefazodone (generics)
MAO Inhibitors (generics)
Tricyclic antidepressants (generics)
Buspirone (generic)
Fluvoxamine (generic)

Medications
Requiring PA:

Mirtazapine (rapid dissolve tablets)
All brand name versions of generics listed above

Public comments were reviewed for the Invega prior authorization criteria. The Board approved the criteria with no changes.

New Business:

Draft insomnia criteria were presented. The following criteria were approved to be released for public comment:

Proposed criteria for insomnia medications
WYDUR
11/29/07

Preferred medications will be zaleplon and zolpidem immediate release.

Claims for non-preferred medications will be approved if:

A 14 day trial of a preferred medication was completed
Rozerem will be approved with a history of substance abuse.

The Department of Health will present information regarding utilization of combination medications and newly approved drugs in January.

Other:

The Board discussed the proposed conflict of interest policy and member communication policy.

Open comments

No open comments were presented.

The Board met to review alert revisions, provider responses and patient profiles. The meeting adjourned at 2 p.m.

Respectfully submitted,

Aimee Lewis
WYDUR Manager